Targeted Radionuclide Therapy and PET Imaging for Prostate and Neuroendocrine Cancers
This community focuses on the development and clinical application of targeted radionuclide therapies and molecular imaging techniques, primarily for treating and diagnosing metastatic prostate cancer and neuroendocrine tumors.
The research centers on the use of specific radioligands, such as PSMA-targeted agents and peptide receptor radionuclide therapies, for both diagnostic imaging via PET and SPECT, and therapeutic intervention. Key recurring themes include the management of castration-resistant prostate cancer, the treatment of neuroendocrine tumors, and the evaluation of targeted alpha and beta-emitting radionuclides. The work involves preclinical evaluation of new radiopharmaceuticals, clinical trials assessing efficacy in patients with bone metastases, and the refinement of imaging protocols for molecular diagnostics.
The largest share of the community's output is found in lutetium research, accounting for 17.9% of all lutetium research, and 1,225 papers here. Radium research also represents a significant portion, with 1,556 papers in this community constituting 7.3% of all radium research.
The community comprises 40,839 papers, published most frequently in the European Journal of Nuclear Medicine and Molecular Imaging, the Journal of Nuclear Medicine, and Nuclear Medicine and Biology.
Recent work includes phase 3 trials evaluating the combination of Lutetium-177 PSMA-617 with androgen deprivation therapy, studies on the molecular blueprint of targeted radionuclide therapy, and consensus guidelines for standardized PSMA PET/CT analysis and reporting.